

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Quinine Sulfate 300mg Tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 300 mg of Quinine Sulfate.

Excipients of known effect: Also contains 34mg of lactose and 156mg of sucrose.

For the full list of excipients see section 6.1

3. PHARMACEUTICAL FORM

Tablet

White, bi-convex, sugar coated tablets

4. CLINICAL PARTICULARS

4.1. Therapeutic Indications

- 1) For the treatment of Plasmodium falciparum (malignant tertian) malaria.
- 2) Treatment and prevention of nocturnal leg cramps in adults and the elderly, when cramps cause regular disruption of sleep (see section 4.2 and section 4.4)

4.2 *Posology and method of administration*

Posology:

For the treatment of falciparum (malignant tertian) malaria

Adults (including the elderly) and children aged 12 years and over: Two tablets (600 mg) to be taken every 8 hours for a period of 7 days. The dose may depend upon the size of the patient, severity of infection, and evidence of renal or liver disease (when the intervals should be increased), due to a prolonged half-life of the drug.

If quinine resistance is known or suspected on completion of the course additional treatment may be given. This may be one of the following:

1. Doxycycline 200mg daily (as a single dose or in 2 divided doses) for at least 7 days.
2. Clindamycin 300mg four times daily for 5 days.

Children aged 11 years and under : Dosage is dependent on bodyweight as follows- 10 mg/kg to be taken every 8 hours for a period of 7 days.

For the treatment and prevention of nocturnal leg cramps:

Adults (including elderly):

The recommended dose is 200mg at bedtime. The maximum dose is 300mg.

A reduction in frequency of leg cramps may take up to 4 weeks to become apparent. Patients should be monitored closely during the early stages of treatment for adverse effects. After an initial trial of 4 weeks, treatment should be stopped if there is no benefit. Treatment should be interrupted at approximately three monthly intervals to reassess the benefit of treatment.

Method of Administration:

For oral administration

4.3 Contraindications

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
- Optic neuritis,
- Tinnitus
- Haemoglobinuria.

- Myasthenia gravis, quinine may cause severe respiratory distress and dysphagia in these patients.

4.4 *Special warnings and precautions for use*

Cinchonism

- Administration of quinine may give rise to cinchonism, which is generally more severe in overdose, but may also occur in normal therapeutic doses. Patients should be warned not to exceed the prescribed dose, because of the possibility of serious, irreversible side effects in overdose. Treatment for night cramps should be stopped if symptoms of cinchonism emerge. Such symptoms include tinnitus, impaired hearing, headache, nausea, and disturbed vision (see sections 4.8 and 4.9).

Hypersensitivity

- Hypersensitivity to quinine may also occur with symptoms of cinchonism together with urticaria, flushing, pruritus, rash, fever, angioedema, dyspnoea and asthma.
- Serious hypersensitivity reactions including Stevens-Johnson syndrome have been reported with quinine.
-

Cardiac disorders

- Quinine has dose-dependent QT-prolonging effects. Caution is recommended in patients with conditions which predispose to QT-prolongation and in patients with atrioventricular block. Quinine should be used with caution in patients with atrial fibrillation, heart block, other cardiac conduction defects, or other serious heart disease. Quinine may cause hypoprothrombinaemia and enhance the effects of anticoagulants.

Glucose-6-phosphate Dehydrogenase (G-6-PD) Deficiency

- The administration of quinine to a patient who has previously been suffering from a chronic and inadequately controlled malarial infection may precipitate an attack of black water fever. However, in some cases deficiency of glucose-6-phosphate dehydrogenase may have been involved.
- Glucose-6-phosphate dehydrogenase deficient patients with malaria or taking quinine to treat leg cramps are at increased risk of haemolytic anaemia during quinine therapy.
- Quinine should not be withheld from pregnant women who have life threatening malaria (see section 4.6).

- Treatment with quinine should be monitored in all patients in case signs of resistance develop.
- Before use for nocturnal leg cramps, the risks, which include significant adverse effects and interactions (see sections 4.5 and 4.8), should be carefully considered relative to the potential benefits. These risks are likely to be of particular concern in the elderly. Quinine should only be considered when cramps are very painful or frequent, when other treatable causes of cramp have been ruled out, and when non-pharmacological measures have not worked. Quinine sulfate should not be used for this indication during pregnancy (see Section 4.6).
- Quinine may cause unpredictable serious and life-threatening thrombocytopenia, which is thought to be in idiosyncratic hypersensitivity reaction. Quinine should not be prescribed or administered to patients who have previously experienced any adverse reaction to quinine, including that in tonic water or other beverages. Patients should be instructed to stop treatment and consult a physician if signs of thrombocytopenia such as unexplained bruising or bleeding occur.
- Reduce the dosage (or increase intervals between doses) in renal or hepatic disease

Important information regarding the ingredients of this medicine

This medicinal product contains sucrose and lactose monohydrate.

Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Patients with rare hereditary problems of fructose intolerance, glucose galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

4.5 *Interaction with other medicinal products and other forms of interaction*

Effect of other drugs on quinine

Quinine is metabolised via hepatic oxidative cytochrome P450 pathways, predominantly by CYP3A4. There is the potential for increased quinine toxicity with concurrent use of potent CYP3A4 inhibitors, which include azole antifungal drugs and HIV protease inhibitors. Sub-optimal quinine serum levels may result from concomitant use of CYP3A4 inducers, which include rifampicin, barbiturates, carbamazepine and phenytoin. Care should be taken when quinine is used in combination with other CYP3A4 substrates, especially those causing prolongation of the QT interval.

Effect of Quinine on other drugs

The plasma concentration of flecainide, digoxin and mefloquine may be increased.

Amantadine: Quinine can reduce the renal clearance of amantadine.

Ciclosporin: Quinine can decrease serum plasma concentrations of ciclosporin.

Cardiac glycosides: Quinine increases plasma concentrations of cardiac glycosides and reduced dosage of concomitant cardiac glycosides such as digoxin to half the maintenance dose may be necessary.

Other drug interactions

Caution is advised when administering quinine with drugs which could prolong the QT interval. There is an increased risk of ventricular arrhythmias with other drugs which prolong the QT interval, including amiodarone, moxifloxacin, pimozide, thioridazine and halofantrine.

Anti-arrhythmics: Concomitant use of amiodarone should be avoided due to the increased risk of ventricular arrhythmias. The plasma concentration of flecainide is increased by quinine. Concomitant use of quinidine may increase the possibility of cinchonism.

Antibacterials: There is an increased risk of ventricular arrhythmias when moxifloxacin is given with quinine. Rifampicin can reduce the serum levels of quinine, therefore reducing its therapeutic effect.

Anticoagulants: Quinine may cause hypoprothrombinaemia and enhance the effects of anticoagulants.

Antihistamines: Concomitant use of terfenadine and astemizole should be avoided due to the increased risk of ventricular arrhythmias.

Antimalarials: According to the manufacturer of artemether with lumefantrine concomitant use should be avoided. There is an increased risk of convulsions when given with mefloquine. Chloroquine and quinine appear to be antagonistic when given together for *P falciparum* malaria. There is a decrease in plasma concentrations of primaquine.

Antipsychotics: There is an increased risk of ventricular arrhythmias and concomitant use should be avoided with pimozide or thioridazine.

Suxamethonium: Quinine enhances the neuromuscular effects of suxamethonium.

Hypoglycaemics: There is an increased risk of hypoglycaemia when taken concurrently.

Ulcer-healing drugs: Cimetidine inhibits quinine metabolism leading to increased plasma-quinine concentrations.

Anti-epileptics: Quinine may increase the levels of phenobarbital and of carbamazepine. Patients should be monitored closely during concomitant use of quinine with these agents.

4.6 Fertility, pregnancy and lactation

Pregnancy

Quinine may cause congenital abnormalities of the CNS and extremities. Following administration of large doses during pregnancy, phototoxicity and deafness have been reported in neonates. Quinine sulfate should not be used during pregnancy unless the benefits outweigh the risks.

Treatment of falciparum malaria

Pregnancy in a patient with malaria is not generally regarded as a contra-indication to the use of quinine. As malaria infection is potentially serious during pregnancy and poses a threat to the mother and foetus, there appears to be little justification in withholding treatment in the absence of a suitable alternative.

Prophylaxis of nocturnal leg-cramps

Quinine sulfate should not be used during pregnancy to treat cramps.

Breast-feeding

Quinine sulfate is excreted in breast milk, but no problems in humans have been reported. Infants at risk for glucose- 6-phosphate dehydrogenase deficiency should not be breast-fed until this disease can be ruled out. However, quinine sulfate should not be given to nursing mothers unless the benefits outweigh the risks.

4.7. Effects on Ability to Drive and Use Machines

Quinine may cause visual disturbances and vertigo, hence patients should be advised that if affected they should not drive or operate machinery.

4.8 Undesirable effects

Adverse drug reactions are ranked by frequency, the most frequent first, using the following convention: very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); very rare ($< 1/10,000$), not known (cannot be estimated from the available data).

MedDRA system organ class	Adverse Reaction
Blood and lymphatic system disorder	Thrombocytopenia, intravascular coagulation, hypoprothrombinaemia, haemoglobinuria, oliguria, haemolytic-uremic syndrome, pancytopenia, haemolysis, agranulocytosis, thrombocytopenic purpura
Immune system disorders	Eczematous dermatitis, oedema, erythema and lichen planus, hypersensitivity reactions including angioneurotic oedema, asthma, photosensitivity, hot and flushed skin, pruritis, thrombocytopenic purpura, urticarial and fever have also been reported.
Metabolism and nutrition disorders	Hypoglycaemia may occur after oral administration although it is more common after parenteral administration.

MedDRA system organ class	Adverse Reaction
Psychiatric disorders	Agitation, confusion
Nervous system disorders	Headache, vertigo, excitement, loss of consciousness, coma and death
Eye disorders	Blurred vision, defective colour perception, visual field constriction
Ear and labyrinth disorders	Tinnitus, impaired hearing
Cardiac disorders	Atrioventricular conduction disturbances, a fall in blood pressure coupled with a feeble pulse, prolongation of the QT interval, widening of the QRS complex and T wave flattening has been noted with therapeutic doses.
Respiratory, thoracic and mediastinal disorders	Bronchospasm, dyspnoea
Gastrointestinal disorders	Nausea, vomiting, diarrhoea, abdominal pain may occur after long term administration of quinine.
Skin and subcutaneous tissue disorders	Flushing, rash, urticaria, eczematous, dermatitis, oedema, erythema, lichen planus, pruritus, photosensitivity, Stevens-Johnson syndrome.
Musculoskeletal and connective tissue disorders	Muscle weakness, aggravation of myasthenia gravis
Renal and urinary disorders	Renal insufficiency, acute renal failure may be due to an immune mechanism or to circulatory failure. Oliguria
Reproductive system and breast disorders	Toxic doses of quinine may induce abortion, but it is unwise to withhold the drug if less toxic anti-malarials are not available

MedDRA system organ class	Adverse Reaction
General disorders and administration site conditions	Cinchonism***

*** More common in overdose, but may occur even after normal doses of quinine. In its mild form symptoms include tinnitus, impaired hearing, rashes, headache, nausea and disturbed vision. Its more severe manifestations symptoms may include gastrointestinal symptoms, oculotoxicity, CNS disturbances, cardiotoxicity and death (see section 4.9). Visual disorders (blurred vision, defective colour perception, visual field constriction and total blindness).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for **MHRA Yellow Card** in the Google Play or Apple App Store .

4.9. Overdose

Symptoms

Quinine overdosage may lead to serious side effects including irreversible visual loss, and can be fatal. In acute overdosage, symptoms of cinchonism may occur, including convulsions, nausea, vomiting, tinnitus, deafness, headache, vasodilation and disturbed vision.

Features of a significant overdose include convulsions, impairment of consciousness, coma, respiratory depression, QT prolongation, ventricular arrhythmia, cardiogenic shock and renal failure. High doses of quinine are teratogenic and may cause miscarriage. Fatalities have been reported in adults after doses of 2-8g. Hypokalaemia and hypoglycaemia may also occur.

Treatment

Children (< 5 years) who have ingested any amount should be referred to hospital.

Older children and adults should be referred to hospital if more than 30 mg/kg of quinine base has been taken. Each 300 mg tablet is equivalent to 248 mg quinine base. Quinine is rapidly absorbed. Consider activated charcoal (50 g for adults; 1 g/kg for

children) if the patient presents within 1 hour of ingestion of more than 30 mg/kg quinine base or any amount in a child under 5 years. Multiple dose activated charcoal will enhance quinine elimination.

Observe patients for at least 12 hours after ingestion. Monitor cardiac conduction and rhythm, serum electrolytes, blood glucose and visual acuity.

Other treatment is symptomatic to maintain blood pressure, respiration, renal function and to treat arrhythmia, convulsions, hypoglycaemia and acidosis.

5 PHARMACOLOGICAL PROPERTIES

5.1 *Pharmacodynamic properties*

ATC Code: P01B C01. Quinine alkaloid

Quinine is a cinchona alkaloid and a 4-methanol-quinolone antimalarial agent which is rapidly acting blood schizontocide with activity against *Plasmodium falciparum*, *P.vivax*, *P.ovale*, and *P.malariae*. It is active against the gametocytes of *P. malariae* and *P. vivax* but not against mature gametocytes of *P. falciparum*. Since it has no activity against exoerythrocytic forms, quinine does not produce a radical cure in vivax or ovale malarias.

Pharmacodynamic effect

Quinine has effects on the motor end-plate of skeletal muscle and prolongs the refractory period. Like quinidine, quinine is a sodium channel blocker and, therefore, has local anaesthetic, and both anti- and proarrhythmic activity.

Mechanism of action

The precise mechanism of action of quinine is unclear but it may interfere with lysosome function or nucleic acid synthesis in the malaria parasite.

5.2. **Pharmacokinetic Properties**

The pharmacokinetics of quinine are altered significantly by malaria infection, the major effects being reduction in both its apparent volume of distribution and its clearance.

Absorption: Quinine is rapidly and almost completely absorbed from the gastrointestinal tract and peak concentrations in the circulation are attained about 1 to 3 hours after oral administration of the sulfate.

Distribution: Plasma protein binding is about 70% in healthy subjects and rises to 90% or more in patients with malaria. Quinine is widely distributed throughout the body. Concentrations attained in the CSF of patients with cerebral malaria have been reported to be about 2 to 7% of those in the plasma.

Biotransformation: Quinine is extensively metabolised in the liver and rapidly excreted mainly in the urine. Estimates of the proportion of unchanged quinine excreted in the urine vary from less than 5% to 20%. The pharmacokinetics of quinine are altered significantly by malaria infection, with reductions in both the apparent volume of distribution and clearance.

Elimination: Excretion is increased in acid urine. The elimination half-life is about 11 hours in healthy subjects but may be prolonged in patients with malaria. Small amounts of quinine also appear in bile and saliva. Quinine crosses the placenta and is excreted in breast milk.

5.3. Preclinical Safety Data

Not applicable.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Lactose

Colloidal Silicon Dioxide

Potato Starch

Magnesium Stearate

Sodium Starch Glycolate (Type A)
Sodium Lauryl Sulfate, Talc
Gelatin
Sucrose
Titanium Dioxide (E171)
Carnauba Wax

6.2 *Incompatibilities*

None known.

6.3 *Shelf life*

3 years.

6.4 *Special precautions for storage*

Tablet Containers: Do not store above 25°C. Store in the original container. Keep the container tightly closed.

Blisters: Do not store above 25°C. Store in the original package. Keep container in the outer carton.

6.5 *Nature and contents of container*

HDPP tablet containers with LDPE caps of 500 tablets.

Al/PVC blisters enclosed in an outer carton, pack sizes 28 and 56 tablets.

6.6 *Special precautions for disposal*

Not applicable.

7 MARKETING AUTHORISATION HOLDER

Bristol Laboratories Ltd
Unit 3, Canalside,
Northbridge Road,
Berkhamsted,
Hertfordshire HP4 1EG
United Kingdom

8 MARKETING AUTHORISATION NUMBER(S)

PL 17907/0011

**9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION**

21/03/2006

10 DATE OF REVISION OF THE TEXT

17/01/2018